Iovance Biotherapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -2.34%182.460.0%$886.10m
AMGNAmgen, Inc. -0.09%246.041.5%$591.52m
NVAXNovavax, Inc. -3.49%58.1775.7%$445.72m
VRTXVertex Pharmaceuticals, Inc. 1.64%292.741.9%$426.74m
GILDGilead Sciences, Inc. 0.66%61.491.0%$374.72m
REGNRegeneron Pharmaceuticals, Inc. 2.30%627.692.6%$352.35m
SNSSSunesis Pharmaceuticals, Inc. 0.00%3.870.7%$270.53m
ILMNIllumina, Inc. -0.33%223.043.3%$240.74m
BIIBBiogen, Inc. -0.37%217.391.8%$200.48m
GOVXGeoVax Labs, Inc. -10.16%2.890.0%$143.97m
BNTXBioNTech SE -9.87%165.030.0%$138.17m
CRSPCRISPR Therapeutics AG 0.08%81.470.6%$132.88m
RYTMRhythm Pharmaceuticals, Inc. 5.02%21.260.0%$95.89m
PLRXPliant Therapeutics, Inc. -0.11%18.890.0%$95.31m
BMRNBioMarin Pharmaceutical, Inc. -0.63%95.224.2%$94.74m

Company Profile

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.